Tocilizumab in COVID-19 therapy: who benefits, and how?

Neumann, Avidan U; Goekkaya, Mehmet; Dorgham, Karim; Traidl-Hoffmann, Claudia; Gorochov, Guy

Neumann, Avidan U; Goekkaya, Mehmet; Dorgham, Karim; Traidl-Hoffmann, Claudia; Gorochov, Guy.

Afiliação

Neumann AU; Department of Environmental Medicine, Faculty of Medicine, Universitätsklinikum Augsburg, Augsburg, Germany; Institute of Environmental Medicine, Helmholtz Center Munich, Augsburg, Germany. Electronic address: avidan.neumann@uni-a.de.
Goekkaya M; Department of Environmental Medicine, Faculty of Medicine, Universitätsklinikum Augsburg, Augsburg, Germany; Environmental Medicine, Technical University Munich, Munich, Germany.
Dorgham K; Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses, Paris, France.
Traidl-Hoffmann C; Department of Environmental Medicine, Faculty of Medicine, Universitätsklinikum Augsburg, Augsburg, Germany; Institute of Environmental Medicine, Helmholtz Center Munich, Augsburg, Germany; Environmental Medicine, Technical University Munich, Munich, Germany.
Gorochov G; Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses, Paris, France; Département d'Immunologie, Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, France.

Lancet ; 398(10297): 299-300, 2021 07 24.

Article em En | MEDLINE | ID: mdl-34303430

Assuntos

Tratamento Farmacológico da COVID-19; Anticorpos Monoclonais Humanizados; Humanos; SARS-CoV-2

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 Limite: Humans Idioma: En Revista: Lancet Ano de publicação: 2021 Tipo de documento: Article País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google